1. Stem Cell Therapy for Acute Graft‑Versus‑Host Disease (aGVHD)
Trial Title: A Single‑Centre Phase II Clinical Study of DPPIV‑Conjugated Sitagliptin Phosphate for the Prevention of Acute Graft‑Versus‑Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Recruitment Period: 15 November 2025 – 31 July 2027
Sponsor: The First Affiliated Hospital of the University of Science and Technology of China (USTC)
Study Objective: To evaluate the safety and efficacy of sitagliptin phosphate (Januvia®) in reducing the incidence of aGVHD in patients undergoing first‑time allogeneic peripheral blood stem cell transplantation (allo‑PBSCT), including haploidentical, matched unrelated, and mismatched unrelated donor transplants.
Target Disease: Acute graft‑versus‑host disease (aGVHD)
Inclusion Criteria:
● Confirmed diagnosis of a haematological disorder (e.g., acute leukaemia, myelodysplastic syndrome, aplastic anaemia, lymphoma);
● Age 18–65 years;
● Planned first allo‑PBSCT;
● ECOG performance status 0–2;
● No severe organ dysfunction or active infection;
● Willing and able to provide written informed consent.
Exclusion Criteria:
● Severe impairment of cardiac, hepatic, renal, or pulmonary function;
● Concomitant central nervous system disease;
● History of pancreatitis or cholelithiasis, or insulin‑requiring diabetes mellitus;
● Pregnancy or breastfeeding;
● Substance abuse, severe psychiatric illness, or cognitive impairment;
● Known allergy to sitagliptin;
● Participation in another interventional trial within a short period;
● Any condition that, in the investigator’s opinion, would compromise protocol adherence or follow‑up.
Contact:
● Principal Investigator: +86 152 5545 6091
● Email: xiaoyuz@ustc.edu.cn
● Address: 17 Lujiang Road, Luyang District, Hefei, Anhui, China
2. Stem Cell Therapy for Diabetic Kidney Disease (DKD)
Sponsor: Department of Nephrology, First Medical Centre, Chinese PLA General Hospital
Trial Title: A Clinical Study to Evaluate the Efficacy and Safety of Aimimetomab Injection in Patients with Diabetic Kidney Disease
Investigational Product: Aimimetomab Injection (conditionally approved by China’s NMPA on 2 January 2025)
Study Objective: Primary – efficacy; secondary – mechanism and safety
Inclusion Criteria:
● Age 45–80 years, male or female;
● Type 2 diabetes mellitus with biopsy‑proven diabetic nephropathy within the past 10 years;
● 24‑h urine protein ≥3.5 g and urine albumin‑to‑creatinine ratio >1000 mg/g;
● veGFR ≥20 mL/min/1.73 m²;
● Blood pressure ≤160/100 mmHg;
● HbA1c <9%;
● Signed informed consent.
Contact:
● Site: First Medical Centre, PLA General Hospital (Outpatient Building, 6th Floor, Nephrology Department – Monday PM & Tuesday AM)
● Principal Investigator: Dr. Li Ping (Associate Chief Physician)
● Project Coordinator: Ms. He
● Enquiry Hotline: 400‑903‑3180
3. Stem Cell Therapy for Premature Ovarian Insufficiency (POI)
Sponsor: Reproductive Medicine Centre, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Study Design: An exploratory clinical study evaluating the safety and efficacy of intra‑ovarian injection of umbilical cord‑derived mesenchymal stem cells (UC‑MSCs) in patients with POI. Final recruitment of 20 participants.
Patient Benefits: All study‑related examinations, cell preparation, ultrasound, laparoscopic injection surgery, anaesthesia, and the use of UC‑MSCs plus recombinant growth hormone are provided free of charge.
Key Entry Criterion: Baseline FSH 15–40 IU/L
Recruitment Period: 1 December 2021 – 31 January 2026
Contact: 186‑0671‑8838; 159‑5801‑0234
4. Stem Cell Therapy for Primary Central Nervous System Lymphoma (PCNSL)
Sponsor: Henan Provincial People’s Hospital
Trial Title: A Clinical Study of Thiotepa Combined with Semustine and Cytarabine as Conditioning Regimen for Autologous Haematopoietic Stem Cell Transplantation in Patients with Primary Central Nervous System Lymphoma
Study Objective: To explore the efficacy and safety of the thiotepa + semustine + cytarabine conditioning regimen for autologous HSCT in PCNSL.
Inclusion Criteria:
● Age 18–70 years;
● PCNSL with at least partial remission (PR) after induction therapy;
● Eligible for autologous HSCT;
● ECOG 0–2;
● Life expectancy ≥3 months;
● Adequate major organ function;
● Sufficient CD34+ stem cell collection;
● Signed informed consent.
Exclusion Criteria:
● Pregnancy or lactation;
● Prior stem cell or bone marrow transplant;
● Other haematological disorders affecting haematopoiesis;
● Allergy to study drugs;
● Severe cardiopulmonary disease or uncontrolled infection;
● Any condition that, in the investigator’s view, would compromise safety or trial completion.
Recruitment Period: 7 November 2025 – 1 October 2028
Contact:
● Principal Investigator: +86 371 65896920
● Email: Yuanxiaoli@126.com
● Address: 7 Weiwu Road, Jinshui District, Zhengzhou, Henan, China
5. Paediatric Haematopoietic Stem Cell Transplant – Exercise Intervention Study
Sponsor: Children’s Hospital of Soochow University
Trial Title: Development and Application of an Exercise Intervention Programme During Paediatric Haematopoietic Stem Cell Transplantation
Study Objective: To establish and validate a feasible exercise intervention protocol for children undergoing HSCT, evaluate its impact on recovery, and create a WeChat mini‑program for broader dissemination.
Inclusion Criteria:
● Age 5–18 years;
● Clinically confirmed need for HSCT.
Exclusion Criteria:
● Contraindications to exercise (e.g., severe neurological disease, musculoskeletal injury, severe heart disease);
● Significant visual/auditory or speech impairment in the child or caregiver;
● Any condition that, in the physician’s opinion, would be aggravated by exercise.
Contact:
● Principal Investigator: +86 13073370828
● Email: wenfang11111@163.com
● Address: 92 Zhongnan Street, Wuzhong District, Suzhou, Jiangsu, China
6. Stem Cell Therapy for Localised Scleroderma (Craniofacial and Limb Skin Involvement)
Sponsor: Peking Union Medical College Hospital
Trial Title: A Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of Local Injection of Human Adipose‑Derived Mesenchymal Stem Cells for Skin Sclerosis in Craniofacial and Limb Areas of Localised Scleroderma
Target Disease: Plaque‑type, linear, or generalised localised scleroderma with lesions on the head/face or extremities
Inclusion Criteria:
● Age 18–60 years;
● Diagnosis of localised scleroderma (plaque, linear, or generalised) with active lesions on the head/face or limbs.
Exclusion Criteria:
● Concurrent other autoimmune diseases;
● Severe organ impairment or active infection;
● History of malignancy;
● Clinically significant laboratory abnormalities;
● Prior stem cell therapy, or recent treatment with phototherapy, laser, or surgery for the lesions;
● Pregnancy, lactation, or planned pregnancy during the study;
● Drug dependence;
● Allergy to study product components or anaesthetic agents;
● Any other condition that, in the investigator’s opinion, would interfere with the study.
Contact:
● Principal Investigator: +86 138 1019 3175
● Email: pumclongxiao@126.com
● Address: 1 Shuaifuyuan, Wangfujing, Beijing 100730, China
7. Stem Cell Therapy for Intrauterine Adhesions (Asherman’s Syndrome)
Sponsor: Shenzhen Third People’s Hospital
Trial Title: A Clinical Trial of Mesenchymal Stem Cell‑Derived Exosomes for the Treatment of Intrauterine Adhesions
Target Population: Women with reduced menstrual flow, infertility, or recurrent miscarriage due to intrauterine adhesions, who wish to restore endometrial function and improve pregnancy outcomes. Planned enrolment: 43 patients.
Entry Criteria (partial):
● Age 18–45 years;
● Desire for fertility or improvement of menstrual abnormalities;
● Diagnosis of intrauterine adhesions confirmed by hysteroscopy or transvaginal ultrasound (final eligibility determined by the study physician).
Contact:
● Address: Gynaecology Office, 19th Floor, Building F, Shenzhen Third People’s Hospital
● Phone: (0755) 61222333‑71951 (Monday–Friday, 8:30–17:00)
● Contact: Dr. Liao
8. Stem Cell Therapy for Refractory Syringomyelia
Sponsor: Department of Neurosurgery, Xuanwu Hospital
Trial Title: A Study to Evaluate the Clinical Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cell‑Derived Exosome Injection (hUC‑MSCs‑EV) in Patients with Refractory Syringomyelia
Inclusion Criteria:
● Age 18–60 years, male or female;
● Confirmed syringomyelia with poor symptom response despite ≥6 months of surgical decompression or long‑term conservative treatment, and MRI showing persistent cavity;
● Women of childbearing age must agree to use effective contraception during and for 6 months after the study.
Contact:
● Prof. Jian Fengzeng (Chief Neurosurgeon) – Wednesday evening special clinic (17:00–20:00)
● Dr. Guan Jian (Associate Chief Neurosurgeon) – Tuesday morning specialist clinic
● Dr. Yuan: 177‑7778‑4396 (also available on WeChat)
9. Stem Cell Therapy for Knee Osteoarthritis
Sponsor: The Second Affiliated Hospital of Zhejiang University School of Medicine
Trial Title: A Multicentre, Randomised, Double‑Blind, Phase II Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for Knee Osteoarthritis
Study Objective: To evaluate the safety, efficacy, and optimal treatment regimen, providing data for Phase III and registration.
Leading Experts: Professor Chen Haijie (State Council Special Allowance expert, National “Ten‑Thousand Talents” Programme) and Academician Su Guohui (Chinese Academy of Sciences).
Background: The product has passed Phase I trials and National Health Commission‑approved stem cell studies at Peking Union Medical College Hospital and Sun Yat‑sen Memorial Hospital.
Inclusion Criteria:
● Age 40–75 years, male or female;
● Diagnosis of knee osteoarthritis according to Chinese guidelines;
● Kellgren‑Lawrence grade II–III on X‑ray;
● Target knee WOMAC pain score 20–42.5 (VAS 0–10 cm) and total WOMAC score 60–180;
● Signed informed consent.
Contact:
Research Assistant Lu: 176‑9966‑4595
Address: The Second Affiliated Hospital, 88 Jiefang Road, Shangcheng District, Hangzhou, Zhejiang, China
10. Stem Cell Therapy for Type 2 Diabetes Mellitus
Sponsors/Coordinators: Beijing Xingdetong Pharmaceutical Technology Co. (CRO) and Beijing Jiyuan Biotechnology Co., in partnership with multiple national centres, including Ruijin Hospital, Qilu Hospital, and Xuanwu Hospital.
Trial Title: A Phase I Clinical Trial of Human GLP‑1 and FGF21 Dual‑Factor Overexpressing Adipose‑Derived Stem Cell Injection in Patients with Type 2 Diabetes
Study Objective: To assess the safety, tolerability, and preliminary efficacy of the product.
Product Features: It promotes both insulin secretion and glucose utilisation through a synergistic mechanism. Previous studies at Ruijin and Xijing Hospitals demonstrated a favourable safety profile and a trend toward reduced insulin requirements.
Main Inclusion Criteria:
● Age 18–65 years, male or female;
● Type 2 diabetes with disease duration 1–10 years;
● On stable GLP‑1 receptor agonist + insulin + other oral hypoglycaemics for ≥3 months;
● HbA1c 7.0%–12.0%;
● Fasting blood glucose <12 mmol/L;
● Fasting C‑peptide ≥0.8 ng/mL;
● BMI 24–40 kg/m².
Patient Benefits:
● Comprehensive evaluation and consultation from expert endocrinology teams;
● All trial‑related medications, visits, laboratory tests, hospital stays, and procedures are free of charge;
● Travel, blood sampling, fat collection, and hospitalisation subsidies are provided as applicable.
Contacts:
● Ruijin Hospital, Shanghai Jiao Tong University School of Medicine: Ms. Zhang, 176‑3357‑9375 (Mon–Fri, 8:00–17:00)
● Qilu Hospital, Shandong University: Ms. Cai, 131‑5616‑2762 (Mon–Fri, 8:00–17:00)
● Xuanwu Hospital, Capital Medical University: Ms. Jiang, 8319‑8899 ext. 9072 (Mon–Fri, 8:00–17:00)
Original source: https://www.hjtdsm.com/zixun/zhaomu/58398.html
WhatsApp
Address
Mailing Form
Languages
English
WhatsApp